MeiraGTx Holdings plc Notes Payable, Noncurrent
MeiraGTx Holdings plc (MGTX) had Notes Payable, Noncurrent of $100.00 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermNotesPayable · last filed 2026-08-13
- 2026-06-30: Notes Payable, Noncurrent $100.00M.
- 2026-03-31: Notes Payable, Noncurrent $49.70M.
- 2025-12-31: Notes Payable, Noncurrent $49.69M.
- 2025-06-30: Notes Payable, Noncurrent $73.77M.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2026-06-30 | $100.00M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $49.70M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $49.69M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $73.77M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $73.50M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $73.22M 10-K · filed 2026-03-30 |
| 2024-09-30 | $72.94M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $72.67M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $72.39M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $72.12M 10-K · filed 2025-03-13 |
| 2023-09-30 | $71.84M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $71.57M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $71.30M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $71.03M 10-K · filed 2024-03-15 |
| 2022-09-30 | $70.84M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |